For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 1,431,157 | 1,219,018 | ||
| Research and development | 402,417 | 1,260,051 | ||
| Depreciation and amortization | 40,369 | 39,980 | ||
| Total operating expenses | 1,873,943 | 2,519,049 | ||
| Loss from operations | -1,873,943 | -2,519,049 | ||
| Other income | - | 0 | ||
| Interest income (expense), net | 274 | -132 | ||
| Total other income (expense) | 274 | -132 | ||
| Net loss before income taxes | -1,873,669 | -2,519,181 | ||
| Income tax expense | - | 0 | ||
| Net loss | -1,873,669 | -2,519,181 | ||
| Less deemed dividend on inducement of warrants | 1,513,449 | - | ||
| Net loss attributable to shareholders | -3,387,118 | - | ||
| Foreign currency translation | -7,414 | 24,473 | ||
| Comprehensive loss | -3,394,532 | -2,494,708 | ||
| Basic EPS | -10.81 | -0.97 | ||
| Diluted EPS | -10.81 | -0.97 | ||
| Basic Average Shares | 313,242 | 2,595,728 | ||
| Diluted Average Shares | 313,242 | 2,595,728 | ||
Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. (ENVB)